HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (<it>cis</it>-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas
<p>Abstract</p> <p>Background</p> <p>Lymphomas frequently retain wild-type (wt) p53 function but overexpress HDM2, thereby compromising p53 activity. Therefore, lymphoma is a suitable model for studying the therapeutic value of disrupting the HDM2-p53 interaction by sma...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-09-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | http://www.jhoonline.org/content/5/1/57 |